Diagnostics agency lands greater than $20 million in new funding previously week, with investments from GHR Basis and ADDF.
Alzheimer’s blood check developer C2N Diagnostics has obtained two key investments to additional its product improvement. Yesterday, the corporate introduced a $15 million program-related funding from the GHR Basis to help the event of a blood check focusing on tau tangle pathology, whereas final week the Alzheimer’s Drug Discovery Basis’s Diagnostics Accelerator offered as much as $7 million in funding to develop a decentralized scientific mass spectrometry platform for scalable Alzheimer’s illness testing.
The funding from the GHR Basis provides to its earlier commitments to C2N, which now whole $50 million since 2020. The brand new tau-based check, specializing in blood biomarkers corresponding to MTBR-tau, has the potential to help in diagnosing Alzheimer’s illness, staging its development and supporting the event of tau-directed therapies. It might additionally present a much less invasive and extra accessible different to tau PET scans.
“Our modern, precision medicine-focused work has already galvanized the science, the analysis, and the platform for growing and commercializing novel diagnostics,” mentioned Dr Joel Braunstein, CEO of C2N, which has already developed a cerebrospinal fluid check for tau pathology for analysis use solely. “Now, we’re poised so as to add exams for tau-based blood biomarkers to our Alzheimer’s illness testing portfolio.”
The funding from the ADDF’s Diagnostics Accelerator initiative helps C2N’s improvement of a completely automated mass spectrometry platform that goals to decentralize high-performance Alzheimer’s illness testing, permitting scientific and analysis labs worldwide to carry out correct diagnostics regionally. The corporate says the platform will observe each amyloid and tau pathology, with the capability to include future assays for different neurodegenerative ailments.
C2N factors to analysis printed within the Journal of the American Medical Association supporting the accuracy of the corporate’s PrecivityAD2 blood check, which is enabled by its mass spectrometry method.
“C2N’s Precivity blood exams reply a essential want for less expensive and extra accessible diagnostic testing in reminiscence and dementia care,” mentioned Dr Howard Fillit, CSO of ADDF. “Their exams are extremely delicate and correct scientific instruments that help healthcare suppliers within the analysis and remedy of Alzheimer’s illness. This new funding in C2N’s LC-MS scientific testing platform brings us nearer to the day when much more sufferers will be capable of depend on blood exams to assist diagnose Alzheimer’s illness.”
